A phase 3 trial of untreated ALK-rearranged NSCLC (CROWN study) demonstrated that the outcomes with lorlatinib were more favorable than those with crizotinib, a first-generation ALK-TKI5. The gene discussed is ALK; the disease is non-small cell lung carcinoma.